GW Pharmaceuticals well positioned at 2008 year end
This article was originally published in Scrip
Executive Summary
GW Pharmaceuticals has ended fiscal 2008 with "no surprises", but in a good position to advance its lead cannabis-based pain-relief drug Sativex in 2009, analysts say.